Sequential Imaging of Asymptomatic Carotid Atheroma Using Ultrasmall Superparamagnetic Iron Oxide–enhanced Magnetic Resonance Imaging: A Feasibility Study

Sadat, Umar; Howarth, Simon; Usman, Ammara; Tang, Tjun Yip; Graves, Martin J.; Gillard, Jonathan H.

doi:10.1016/j.jstrokecerebrovasdis.2012.06.015

Cited by 27 publications

(51 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14 Furthermore, ferumoxtran-enhanced MRI has been shown to predict the expansion and rupture of aortic aneurysms 15 and detect inflammation following ischemic stroke. 16 Importantly, sequential USPIO-enhanced MRI in patients suffering from stenosis of carotid arteries 17 provided evidence that, within 6 months, ferumoxtran particles administered at 2.6 mg Fe/kg were cleared out of the plaque, with no major adverse effects observed following multiple infusions. 17 In contrast to USPIO, SPIONs are characterized by enhanced liver accumulation, thereby constituting a superb hepatic MRI contrast agent.…”

Section: Introductionmentioning

confidence: 99%

“…16 Importantly, sequential USPIO-enhanced MRI in patients suffering from stenosis of carotid arteries 17 provided evidence that, within 6 months, ferumoxtran particles administered at 2.6 mg Fe/kg were cleared out of the plaque, with no major adverse effects observed following multiple infusions. 17 In contrast to USPIO, SPIONs are characterized by enhanced liver accumulation, thereby constituting a superb hepatic MRI contrast agent. Low concentrations of SPIONs (0.5 mg Fe/kg of carboxydextran-coated ferucarbotran (Resovist/Ferrixan, 45-60 nm [18][19][20], or dextran-coated ferumoxides (Endorem/Feridex), 21 have been used to noninvasively distinguish between benign liver condition (simple steatosis) and nonalcoholic steatohepatitis (NASH), which is highly associated with cardiovascular and renal comorbidities.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Non-immunogenic dextran-coated superparamagnetic iron oxide nanoparticles: a biocompatible, size-tunable contrast agent for magnetic resonance imaging

Unterweger

Janko

Schwarz

et al. 2017

IJN

View full text Add to dashboard Cite

Iron oxide-based contrast agents have been in clinical use for magnetic resonance imaging (MRI) of lymph nodes, liver, intestines, and the cardiovascular system. Superparamagnetic iron oxide nanoparticles (SPIONs) have high potential as a contrast agent for MRI, but no intravenous iron oxide-containing agents are currently approved for clinical imaging. The aim of our work was to analyze the hemocompatibility and immuno-safety of a new type of dextran-coated SPIONs (SPIONdex) and to characterize these nanoparticles with ultra-high-field MRI. Key parameters related to nanoparticle hemocompatibility and immuno-safety were investigated in vitro and ex vivo. To address concerns associated with hypersensitivity reactions to injectable nanoparticulate agents, we analyzed complement activation-related pseudoallergy (CARPA) upon intravenous administration of SPIONdex in a pig model. Furthermore, the size-tunability of SPIONdex and the effects of size reduction on their biocompatibility were investigated. In vitro, SPIONdex did not induce hemolysis, complement or platelet activation, plasma coagulation, or leukocyte procoagulant activity, and had no relevant effect on endothelial cell viability or endothelial–monocytic cell interactions. Furthermore, SPIONdex did not induce CARPA even upon intravenous administration of 5 mg Fe/kg in pigs. Upon SPIONdex administration in mice, decreased liver signal intensity was observed after 15 minutes and was still detectable 24 h later. In addition, by changing synthesis parameters, a reduction in particle size <30 nm was achieved, without affecting their hemo- and biocompatibility. Our findings suggest that due to their excellent biocompatibility, safety upon intravenous administration and size-tunability, SPIONdex particles may represent a suitable candidate for a new-generation MRI contrast agent.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Non-immunogenic dextran-coated superparamagnetic iron oxide nanoparticles: a biocompatible, size-tunable contrast agent for magnetic resonance imaging

Unterweger

Janko

Schwarz

et al. 2017

IJN

View full text Add to dashboard Cite

show abstract

“…These particles consist of an iron oxide core, which is coated with organic materials such as fatty acids, polysaccharides or polymers. Iron oxide nanoparticles have good biocompatibility and contrast-enhancing properties in MRI, enabling plaque detection and characterization [17][18][19][20]. Furthermore, the magnetic properties of these particles could allow their remote targeting by means of external magnetic field [21][22][23].…”

mentioning

confidence: 99%

Nanoparticles for Intravascular Applications: Physicochemical Characterization and Cytotoxicity Testing

Matuszak

Baumgartner

Zaloga

et al. 2016

Nanomedicine (Lond.)

View full text Add to dashboard Cite

Aim:We report the physicochemical analysis of nanosystems intended for cardiovascular applications and their toxicological characterization in static and dynamic cell culture conditions. Methods: Size, polydispersity and ζ-potential were determined in 10 nanoparticle systems including liposomes, lipid nanoparticles, polymeric and iron oxide nanoparticles. Nanoparticle effects on primary human endothelial cell viability were monitored using real-time cell analysis and live-cell microscopy in static conditions, and in a flow model of arterial bifurcations. Results & conclusions: The majority of tested nanosystems were well tolerated by endothelial cells up to the concentration of 100 μg/ml in static, and up to 400 μg/ml in dynamic conditions. Pilot experiments in a pig model showed that intravenous administration of liposomal nanoparticles did not evoke the hypersensitivity reaction. These findings are of importance for future clinical use of nanosystems intended for intravascular applications.

show abstract

“…In 2013, a new study from the group of J.H. Gillard was published, investigating for the first time the feasibility of longitudinal sequential MR imaging before and 36 h after USPIO infusion at 0, 6, and 12 months, in 10 patients with a moderate asymptomatic carotid stenosis (122). The patients, none of whom received pharmacotherapy, remained asymptomatic within the course of the study and there was no statistical difference in their USPIO uptake between the three time points.…”

Section: Pilot Studies -Cardiovascular Imagingmentioning

confidence: 99%

Cardiovascular therapy through nanotechnology – how far are we still from bedside?

Cicha¹,

Garlichs²,

Alexiou³

2014

European Journal of Nanomedicine

View full text Add to dashboard Cite

Abstract:Recent years brought about a widespread interest in the potential applications of nanotechnology for the diagnostics and the therapy of human diseases. With its promise of disease-targeted, patient-tailored treatment and reduced side effects, nanomedicine brings hope for millions of patients suffering of non-communicable diseases such as cancer or cardiovascular disorders. However, the emergence of the complex, multicomponent products based on new technologies poses multiple challenges to successful approval in clinical practice. Regulatory and development considerations, including properties of the components, reproducible manufacturing and appropriate characterization methods, as well as nanodrugs' safety and efficacy are critical for rapid marketing of the new products. This review discusses the recent advances in cardiovascular applications of nanotechnologies and highlights the challenges that must be overcome in order to fill the gap existing between the promising bench trials and the successful bedside applications.

show abstract

Sequential Imaging of Asymptomatic Carotid Atheroma Using Ultrasmall Superparamagnetic Iron Oxide–enhanced Magnetic Resonance Imaging: A Feasibility Study

Cited by 27 publications

References 20 publications

Non-immunogenic dextran-coated superparamagnetic iron oxide nanoparticles: a biocompatible, size-tunable contrast agent for magnetic resonance imaging

Non-immunogenic dextran-coated superparamagnetic iron oxide nanoparticles: a biocompatible, size-tunable contrast agent for magnetic resonance imaging

Nanoparticles for Intravascular Applications: Physicochemical Characterization and Cytotoxicity Testing

Cardiovascular therapy through nanotechnology – how far are we still from bedside?

Contact Info

Product

Resources

About